Amarin Corp Plc (AMRN)

[Jt0082]

studying this ESC discussion from 5mins 15 seconds with Dr Bhatt as R-IT principal investigator makes me believe :

1. the dosage matters 'IF' there is going to be a benefit.
2. the level of baseline trigs matters too, still hopefully they enrolled enough high trigs.
3. even Dr Bhatt the key investigator doesn't know if 'it will be enough' to matter in outcomes data, 'thats why we do clinical trials'

this makes me think:

- nobody really knows the data yet at all - flyfishstocks charting leak theories unfounded
- Dr Bhatt is either very quiet knowing the answer or has no idea of the magnitude of RRR yet, if any.


Any experts in body language want to chime in?